HomeAI · summaries
Storia in 3 fonti
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal
J&J and AbbVie reviewed AtaiBeckley data but couldn't beat Lilly's $2.8B deal for the psychedelics company and maker of rapid-acting depression drug BPL-003.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
- ·
forbes.com
Big Pharma And Psychedelic Medicine: Eli Lilly’s $3.8 Billion Bet
Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, marks a pivotal moment for psychedelic medicine.
